Survival and Glycemic Control in Patients With Colorectal Cancer and Diabetes Mellitus

Karlin, Nina J.; Amin, Shailja; Kosiorek, Heidi E.; Buras, Matthew R.; Verona, Patricia M; Cook, Curtiss B.

doi:10.4155/fsoa-2018-0044

Cited by 14 publications

(17 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this regard, in a cohort study, diabetes mellitus was not associated with any cancer such as CRC [51, 52]. It appears that diabetes mellitus does not decrease the survival of the CRC patients and CRC does not have a significant impact on glucose level of patients with diabetes mellitus [53, 54]. In a study with 3000 CRC cases which were followed up to 32 years, type 2 diabetes was significantly associated with high risk of CRC in comparison to controls but only among men [55].…”

Section: Discussionmentioning

confidence: 99%

Obesity, diabetes and the risk of colorectal adenoma and cancer

et al. 2019

View full text Add to dashboard Cite

BackgroundColorectal cancer (CRC) is the fourth most commonly diagnosed gastrointestinal (GI) malignancy and the third leading cause of cancer-related death worldwide. In the current case-control study, an association between diagnosis of CRC, obesity and diabetes was investigated.MethodsDemographic characteristics, colonoscopy reports, history of drug, smoking, and medical history were collected from patients referred to a colonoscopy unit. The location, size and number of the polyps were recorded during the colonoscopy. Statistically, t-test was conducted for mean comparison for the groups. Pearson’s chi-squared test (χ2) was applied to categorize variables. Five classification methods based on the important clinicopathological characteristics such as age, BMI, diabetes, family history of colon cancer was performed to predict the results of colonoscopy.ResultsOverall, 693 patients participated in this study. In the present study, 115 and 515 patients were evaluated for adenoma/adenocarcinoma and normal colonoscopy, respectively. The mean age of patients positive for adenoma or adenocarcinoma were significantly higher than the negative groups (p value < 0.001). Incidence of overweight and/or obesity (BMI > 25 kg/m2) were significantly higher in adenoma positive patients as compared to controls (49.9 and 0.9% respectively, p value = 0.04). The results also demonstrated a significant association between suffering from diabetes and having colon adenoma (OR = 1.831, 95%CI = 1.058–3.169, p value = 0.023). The experimental results of 5 classification methods on higher risk factors between colon adenoma and normal colonoscopy data were more than 82% and less than 0.42 for the percentage of classification accuracy and root mean squared error, respectively.ConclusionsIn the current study, the occurrence of obesity measured based on BMI and diabetes in the adenoma positive patient group was significantly higher than the control group although there was no notable association between obesity, diabetes and adenocarcinoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Obesity, diabetes and the risk of colorectal adenoma and cancer

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Our previously published case-matched studies for colorectal, pancreatic, lung and prostate cancers did not show an interaction between DM and cancer survival [ 22–25 ]. The only exception was for patients with gastroesophageal cancers, where we did find that patients with preexisting DM had a higher risk of death than those without DM [ 26 ].…”

Section: Discussionmentioning

confidence: 99%

“…Patient data collected from the electronic health record included demographic information and co-morbid conditions, cancer location and date of diagnosis, histology if available, therapy, and survival. Cancer data were linked to the electronic health record to identify individuals with DM, as previously described [ 22–27 ]. For patients with DM, data collected included diabetic therapy, HbA 1c , glucose levels and complications of DM before and after cancer diagnosis.…”

Section: Methodsmentioning

confidence: 99%

Implications of Neuroendocrine Tumor and Diabetes Mellitus on Patient Outcomes and Care: a Matched case–control Study

et al. 2021

Self Cite

View full text Add to dashboard Cite

Aim: We aimed to determine the impact of diabetes mellitus (DM) on survival of patients with neuroendocrine tumors (NETs) and of NETs on glycemic control. Patients & methods: Patients with newly diagnosed NETs with/without DM were matched 1:1 by age, sex and diagnosis year (2005–2017), and survival compared (Kaplan–Meier and Cox proportional hazards). Mixed models compared hemoglobin A1c (HbA1c) and glucose during the year after cancer diagnosis. Results: Three-year overall survival was 72% (95% CI: 60–86%) for DM patients versus 80% (95% CI: 70–92%) for non-DM patients (p = 0.82). Hazard ratio was 1.33 (95% CI: 0.56–3.16; p = 0.51); mean DM HbA1c, 7.3%. Conclusion: DM did not adversely affect survival of patients with NET. NET and its treatment did not affect glycemic control.

show abstract

“…Previous studies usually compared the trajectory of glycemic control before and after the cancer diagnosis while no control group of patients without cancer was introduced [16]. These studies were also further limited by a small sample size and a short follow-up [17][18][19].…”

Section: Introductionmentioning

confidence: 99%

Glycemic Control for Colorectal Cancer Survivors Compared to Those without Cancer in the Dutch Primary Care for Type 2 Diabetes: A Prospective Cohort Study

Landman

Kleefstra

Schrijnders³

et al. 2021

Cancers

View full text Add to dashboard Cite

Cancer survivors with diabetes tend to have worse glycemic control after their cancer diagnosis, which may increase the risk of cardiovascular diseases. We aimed to investigate whether glycemic control differs between colorectal cancer (CRC) survivors and those without cancer, among patients with type 2 diabetes being treated in the Dutch primary care. The Zwolle Outpatient Diabetes project Integrating Available Care database was linked with the Dutch Cancer Registry (n = 71,648, 1998–2014). The cases were those with stage 0–III CRC, and the controls were those without cancer history. The primary and secondary outcomes were the probability of reaching the glycated hemoglobin (HbA1c) target and the mean of HbA1c during follow-up, respectively. Mixed linear modeling was applied, where the status of CRC was a time-varying variable. Among the 57,330 patients included, 705 developed CRC during follow-up. The mean probability of reaching the HbA1c target during follow-up was 73% versus 74% (p = 0.157) for CRC survivors versus those without cancer, respectively. The mean HbA1c was 51.1 versus 50.8 mmol/mol (p = 0.045) among CRC survivors versus those without cancer, respectively. We observed a clinically comparable glycemic control among the CRC survivors without cancer, indicating that glycemic control for CRC survivors can be delegated to primary care professionals.

show abstract

Survival and Glycemic Control in Patients With Colorectal Cancer and Diabetes Mellitus

Cited by 14 publications

References 21 publications

Obesity, diabetes and the risk of colorectal adenoma and cancer

Obesity, diabetes and the risk of colorectal adenoma and cancer

Implications of Neuroendocrine Tumor and Diabetes Mellitus on Patient Outcomes and Care: a Matched case–control Study

Glycemic Control for Colorectal Cancer Survivors Compared to Those without Cancer in the Dutch Primary Care for Type 2 Diabetes: A Prospective Cohort Study

Contact Info

Product

Resources

About